Incyte_J.P. Morgan Slides 2025_vFINAL.pdf

1、2025:A Year of Defining CatalystsJ.P.Morgan Healthcare ConferenceHerv Hoppenot|January 13th,20252Forward Looking StatementsExcept for the historical information set forth herein,the matters set forth in this presentation contain predictions,estimates and other forward-looking statements,including wi

2、thout limitation statements regarding:the opportunities for growth presented by Incytes pipeline and products;expectations regarding Incytes R&D and commercial execution;expected revenue contribution from near-term launches;additional label expansion opportunities;projected launches,pivotal readouts

3、,phase 3 study initiations and proof of concept readouts;the timing of clinical trials and regulatory submissions;potential high impact launches and high impact pipeline programs;Incytes positioning for 2026 and beyond;and expectations regarding 2025 catalysts and newsflow items.These forward-lookin

4、g statements are based on Incytes current expectations and subject to risks and uncertainties that may cause actual results to differ materially,including unanticipated developments in and risks related to:future research and development,including the possibility that clinical trials will be unsucce

5、ssful or otherwise fail to meet applicable regulatory standards and/or warrant continued development;the ability to enroll sufficient numbers of subjects in clinical trials,including the ability to enroll subjects in accordance with planned schedules;determinations made by FDA and other regulatory a

6、gencies;Incytes relationships with its collaboration partners;the efficacy or safety of Incytes products;the acceptance of Incytes products in the marketplace;market competition;variations in demand for Incytes products;price regulation or limitations on reimbursement/coverage for Incytes products;s